Physician profile
Jenna Yoder
NPI 1982946471
$3,080.47
in general payments reported to CMS, 2019-2025
16 companies · $1,167 in 2025
The $1,167 reported for 2025 was more than what 81% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $258 · 2020: $202 · 2021: $39.83 · 2022: $210 · 2023: $519 · 2024: $686 · 2025: $1,167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,372.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,371.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,025.06 | 2023-2025 | Durysta, Alphagan P, Lumigan |
| Glaukos Corporation | $920.01 | 2019-2025 | Istent Trabecular Micro-Bypass System Model Is3, Idosetr, Istent Infinite |
| Sight Sciences, INC. | $199.89 | 2022-2025 | Omni Surgical System, Sion Surgical Instrument |
| Allergan, INC. | $187.80 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $141.04 | 2019-2021 | |
| Alcon Vision LLC | $135.28 | 2022-2025 | Rocklatan |
| Johnson & Johnson Surgical Vision, INC. | $125.00 | 2020 | |
| Bausch & Lomb Americas INC. | $113.65 | 2022-2025 | Vyzulta, Miebo |
| Novartis Pharmaceuticals Corporation | $55.34 | 2019-2022 | |
| Kala Pharmaceuticals, INC. | $34.14 | 2020 | |
| New World Medical,INC. | $33.62 | 2019-2025 | Ahmed Glaucoma Valve, Kahook Dual Blade, Streamline |
| Biotissue Holdings INC. | $24.19 | 2025 | |
| Thea Pharma INC. | $23.59 | 2023 | Iyuzeh |
| Horizon Therapeutics Plc | $23.59 | 2023 | Tepezza |
| Iridex Corporation | $20.62 | 2023 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $17.65 | 2025 | Izervay |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenna Yoder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.